ストックスクリーナーアプリを入手
9.38
1.08%
0.10
プレマーケット:
9.01
-0.37
-3.94%
前日終値:
$9.28
開ける：
$9.6
24時間の取引高:
65,266
Relative Volume:
2.98
時価総額：
$47.13M
収益：
-
当期純損益:
$-168.86M
株価収益率:
-5.5833
EPS:
-1.68
ネットキャッシュフロー:
$-125.29M
1週間 パフォーマンス:
+1.96%
1か月 パフォーマンス:
+0.95%
6か月 パフォーマンス:
-45.24%
1年 パフォーマンス:
-40.03%
1日の値動き範囲:
$9.01
$9.76
1週間の範囲:
$7.96
$10.35
52週間の値動き範囲:
$7.96
$24.15
Allovir Inc Stock (ALVR) Company Profile
ALVR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALVR
Allovir Inc
|
9.38 | 47.13M | 0 | -168.86M | -125.29M | -1.68 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Allovir Inc Stock (ALVR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-12-26 | ダウングレード | BofA Securities | Buy → Underperform |
| 2023-12-22 | ダウングレード | JP Morgan | Overweight → Underweight |
| 2023-12-22 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2023-12-22 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2023-08-18 | 開始されました | BofA Securities | Buy |
| 2021-10-19 | 再開されました | Morgan Stanley | Overweight |
| 2020-08-24 | 開始されました | JP Morgan | Overweight |
| 2020-08-24 | 開始されました | Morgan Stanley | Overweight |
| 2020-08-24 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Allovir Inc (ALVR) 最新ニュース
ALVR LAWSUIT ALERT: Levi & Korsinsky Notifies AlloVir, Inc. Inve - GuruFocus.com
AlloVir (NASDAQ:ALVR) Trading 8.2% HigherHere's What Happened - MarketBeat
The Law Offices of Vincent Wong Remind AlloVir Investors of a Lead Plaintiff Deadline of March 19, 2024 - Marketscreener.com
Shareholders that lost money on AlloVir, Inc.(ALVR) should contact Levi & Korsinsky about pending Class ActionALVR - Marketscreener.com
AlloVir (NASDAQ:ALVR) Hits New 1-Year LowWhat's Next? - MarketBeat
SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their Options - Marketscreener.com
ALLOVIR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AlloVir, Inc.ALVR - Marketscreener.com
Levi & Korsinsky Notifies Shareholders of AlloVir, Inc.(ALVR) of a Class Action Lawsuit and an Upcoming Deadline - Marketscreener.com
Shareholder Alert: Ademi LLP Investigates Whether AlloVir, Inc. Is Obtaining a Fair Price for Its Public Shareholders - Marketscreener.com
AlloVir, Inc. Enter into Termination of Sublease Agreement with AMAG Pharmaceuticals, Inc - Marketscreener.com
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allovir - Marketscreener.com
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 19, 2024 in AlloVir, Inc. LawsuitALVR - Marketscreener.com
Jane Street Group LLC Sells 89,680 Shares of AlloVir, Inc. (NASDAQ:ALVR) - Defense World
AlloVir executes reverse stock split - Investing.com
AlloVir executes reverse stock split By Investing.com - Investing.com UK
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Allovir stock plunges to 52-week low, touches $0.4 By Investing.com - Investing.com Canada
Allovir’s Vikas Sinha sells shares worth $430 By Investing.com - Investing.com Nigeria
Allovir's Vikas Sinha sells shares worth $430 By Investing.com - Investing.com Australia
Allovir’s general counsel Edward Miller sells $180 in stock By Investing.com - Investing.com Nigeria
Allovir’s chief accounting officer sells $146 in common stock By Investing.com - Investing.com Nigeria
Allovir's chief accounting officer sells $146 in common stock By Investing.com - Investing.com Australia
Allovir's general counsel Edward Miller sells $180 in stock By Investing.com - Investing.com Australia
Allovir's chief accounting officer sells $146 in common stock - Investing.com India
Allovir's general counsel Edward Miller sells $180 in stock - Investing.com India
Allovir's Vikas Sinha sells shares worth $430 - Investing.com
Allovir stock plunges to 52-week low, touches $0.4 - Investing.com India
Geode Capital Management LLC Lowers Stock Position in AlloVir, Inc. (NASDAQ:ALVR) - Defense World
Reviewing AlloVir (NASDAQ:ALVR) and Turnstone Biologics (NASDAQ:TSBX) - Defense World
AlloVir, Inc. Reports Positive Voting Outcome for Proposed Reverse Stock Split - Defense World
AlloVir announces reverse stock split effective January 16 By Investing.com - Investing.com Australia
AlloVir announces reverse stock split effective January 16 - Investing.com India
AlloVir shareholders approve reverse stock split - Investing.com
Shareholders that lost money on AlloVir, Inc.(ALVR) should conta - GuruFocus.com
ALLOVIR, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP Announces That a Class Action Lawsuit Has Been Filed in the United States District Court for the District of Massachusetts Against AlloVir, Inc. - AccessWire
Short Interest in AlloVir, Inc. (NASDAQ:ALVR) Drops By 12.0% - Defense World
AlloVir, Inc. (NASDAQ:ALVR) Short Interest Update - MarketBeat
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVTE, STAF, ALVR on Behalf of Shareholders - The Eastern Progress Online
AlloVir, Inc. (NASDAQ:ALVR) Shares Sold by Charles Schwab Investment Management Inc. - Defense World
AlloVir appoints new CEO following leadership shakeup - Investing.com India
AlloVir Appoints Vikas Sinha as New CEO - TipRanks
AlloVir appoints new CEO following leadership shakeup By Investing.com - Investing.com South Africa
AlloVir CEO Departs, CFO Steps In - MarketWatch
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALVR, CDMO, EMKR on Behalf of Shareholders - The Eastern Progress Online
Allovir stock touches 52-week low at $0.47 amid market challenges - Investing.com
AlloVir (NASDAQ:ALVR) Stock Price Down 1.2%What's Next? - MarketBeat
Allovir Inc (ALVR) 財務データ
収益
当期純利益
現金流量
EPS
4.81%
大文字化:
|
ボリューム (24 時間):